TABLE 4

Univariate analysis of clinical and treatment-related factors associated with acute kidney disease during pemetrexed maintenance

	Primary cohort^#		Independent cohort^¶
	OR (95% CI)	p-value	OR (95% CI)	p-value
Age	1.07 (0.98–1.18)	0.14	0.98 (0.89–1.07)	0.62
*Sex: male versus* female**	0.52 (0.14–1.93)	0.34	0.28 (0.068–1.11)	0.069
*History of cardiovascular disease: yes versus* no**	0.70 (0.18–2.80)	0.62	0.73 (0.21–2.53)	0.62
*CISPEM during induction: yes versus* no**	2.62 (0.49–14.11)	0.26	0.94 (0.23–3.90)	0.93
Number of cycles pemetrexed maintenance	1.08 (1.0–1.17)	0.059	1.09 (0.96–1.23)	0.2
eGFR decrease during induction⁺	2.54 (1.36–4.74)	0.004	1.56 (1.03–2.36)	0.038
eGFR before induction^§	0.78 (0.62–0.98)	0.032	0.78 (0.62–0.98)	0.035
eGFR before maintenance^§	0.70 (0.54–0.90)	0.005	0.64 (0.48–0.84)	0.001

CISPEM: combined cisplatin and pemetrexed; eGFR: estimated glomerular filtration rate. ^#: n=44; ^¶: n=41; ⁺: eGFR change relative to baseline per 10%; ^§: eGFR per unit 5 mL min⁻¹ per 1.73 m².